PharmaCielo Ltd.
PCLOF
$0.03
-$0.01-17.21%
OTC PK
| 06/30/2025 | 09/30/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -59.30% | 271.59% | 382.07% | 382.07% | -69.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.30% | 271.59% | 382.07% | 382.07% | -69.36% |
| Cost of Revenue | -25.52% | 34.32% | -35.02% | -35.02% | -34.60% |
| Gross Profit | -121.86% | 204.73% | 144.28% | 144.28% | -106.71% |
| SG&A Expenses | -56.85% | -36.23% | -19.28% | -19.28% | -55.46% |
| Depreciation & Amortization | -60.81% | -42.41% | -54.60% | -54.60% | 5.78% |
| Other Operating Expenses | -703.75% | 9.25% | 8.05% | 8.05% | 87.92% |
| Total Operating Expenses | -57.23% | -18.12% | -24.39% | -24.39% | -48.59% |
| Operating Income | 56.25% | 62.57% | 45.93% | 45.93% | 43.28% |
| Income Before Tax | 50.03% | 5.83% | 29.47% | 29.47% | 31.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.03% | 5.83% | 29.47% | 29.47% | 31.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.03% | 5.83% | 29.47% | 29.47% | 31.79% |
| EBIT | 56.25% | 62.57% | 45.93% | 45.93% | 43.28% |
| EBITDA | 46.34% | 57.59% | 40.44% | 51.29% | 39.81% |
| EPS Basic | 54.95% | 5.51% | 34.71% | 34.71% | 37.65% |
| Normalized Basic EPS | 55.07% | 34.18% | 34.91% | 34.91% | 36.45% |
| EPS Diluted | 54.95% | 5.51% | 34.71% | 34.71% | 37.65% |
| Normalized Diluted EPS | 55.07% | 34.18% | 34.91% | 34.91% | 36.45% |
| Average Basic Shares Outstanding | 10.74% | 0.00% | 8.22% | 8.22% | 9.14% |
| Average Diluted Shares Outstanding | 10.74% | 0.00% | 8.22% | 8.22% | 9.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |